NO20062410L - Malretting av ERB-antigener - Google Patents

Malretting av ERB-antigener

Info

Publication number
NO20062410L
NO20062410L NO20062410A NO20062410A NO20062410L NO 20062410 L NO20062410 L NO 20062410L NO 20062410 A NO20062410 A NO 20062410A NO 20062410 A NO20062410 A NO 20062410A NO 20062410 L NO20062410 L NO 20062410L
Authority
NO
Norway
Prior art keywords
biotin
erb
linker
binding
targeting
Prior art date
Application number
NO20062410A
Other languages
English (en)
Inventor
Bengt E B Sandberg
Rune Nilsson
Original Assignee
Mitra Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0303229A external-priority patent/SE0303229D0/xx
Application filed by Mitra Medical Ab filed Critical Mitra Medical Ab
Publication of NO20062410L publication Critical patent/NO20062410L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det beskrives et konjugat omfattende a) en trifunksjonell kryssbindende enhet, hvortil det er koplet b) en affinitetsligand via en linker 1, c) et cytotoksisk middel, valgfritt via en linker 2 og d) et anti Erb-antistoff eller varianter derav som har evnen til å binde til Erb-antigener uttrykt på mammaiske tumoroverflater med en affinitetsbindingskonstant på minst 5x106M-1 , hvor affinitetsliganden er biotin, eller et biotinderivat som har i hovedsak samme bindingsfunksjon til avidin eller streptavidin som biotin, hvor stabiliteten mot enzymatisk spalting av biotinamidbindingen har blitt introdusert i linker 1.
NO20062410A 2003-11-28 2006-05-26 Malretting av ERB-antigener NO20062410L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52570303P 2003-11-28 2003-11-28
SE0303229A SE0303229D0 (sv) 2003-11-28 2003-11-28 Targeting of Erb antigens
PCT/SE2004/001753 WO2005051424A1 (en) 2003-11-28 2004-11-26 Targeting of erb antigens

Publications (1)

Publication Number Publication Date
NO20062410L true NO20062410L (no) 2006-08-24

Family

ID=34635770

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062410A NO20062410L (no) 2003-11-28 2006-05-26 Malretting av ERB-antigener

Country Status (11)

Country Link
US (1) US20080267865A1 (no)
EP (1) EP1708750A1 (no)
JP (1) JP2007512324A (no)
KR (1) KR20070003806A (no)
AU (1) AU2004292933B2 (no)
BR (1) BRPI0416987A (no)
CA (1) CA2547435A1 (no)
MX (1) MXPA06006009A (no)
NO (1) NO20062410L (no)
RU (1) RU2006122952A (no)
WO (1) WO2005051424A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007306927B2 (en) * 2006-10-11 2013-10-03 Aushealth Corporate Pty Ltd The use of a DNA damaging agent and a ligand for the treatment of cancer
EP2606911A1 (en) 2007-02-16 2013-06-26 KTB Tumorforschungsgesellschaft mbH Receptor And Antigen Targeted Prodrug
WO2009012288A2 (en) * 2007-07-17 2009-01-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Trifunctional imaging agent for monoclonal antibody tumor-targeted imaging
HRP20151367T1 (hr) * 2008-05-13 2016-01-29 Yale University Kimerne male molekule za pojaäśanje odgovora protutijela na stanice raka
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
EP2359852A4 (en) 2008-11-17 2015-05-20 Nat Cancer Ct NEW CANCERED THERAPY WITH A SUBSTANCE COMPLEX SPECIFICALLY BINDING TO A TUMOR STREAM FACTOR AND ANTITUMIR COMPOUND
WO2011071447A1 (en) * 2009-12-10 2011-06-16 Nicholls Ian A Molecular imprints
GB201205360D0 (en) 2012-03-27 2012-05-09 Univ Edinburgh Biotinidase resistant biotinyl compounds
US11745029B2 (en) 2018-05-30 2023-09-05 Zap Surgical Systems, Inc. Radiosurgical neuromodulation close to critical structures

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5630978A (en) * 1995-06-07 1997-05-20 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Preparation of biologically active molecules by molecular imprinting
US20010023288A1 (en) * 1999-07-07 2001-09-20 Wilbur D. Scott Trifunctional reagent for conjugation to a biomolecule
US7141676B1 (en) * 1996-02-08 2006-11-28 University Of Washington Water soluble multi-biotin-containing compounds
WO2000002050A1 (en) * 1998-07-07 2000-01-13 Department Of Radiation Oncology, University Of Washington Trifunctional reagent for conjugation to a biomolecule
US7244826B1 (en) * 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US20050271673A1 (en) * 1998-07-07 2005-12-08 Wilbur D S Trifunctional reagent for conjugation to a biomolecule
EP2977063A1 (en) * 1999-06-25 2016-01-27 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
AR024464A1 (es) * 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
SE0002287D0 (sv) * 2000-06-16 2000-06-16 Department Of Radiation Oncolo Biotinderivat
CA2478543A1 (en) * 2001-10-26 2003-04-26 The Uab Research Foundation Multidrug multiligand conjugates for targeted drug delivery
SE0203731D0 (sv) * 2002-12-13 2002-12-13 Mitra Medical Technology Ab Reagent

Also Published As

Publication number Publication date
KR20070003806A (ko) 2007-01-05
WO2005051424A1 (en) 2005-06-09
BRPI0416987A (pt) 2007-08-21
EP1708750A1 (en) 2006-10-11
MXPA06006009A (es) 2006-09-04
AU2004292933A1 (en) 2005-06-09
RU2006122952A (ru) 2008-01-10
AU2004292933B2 (en) 2011-01-06
JP2007512324A (ja) 2007-05-17
US20080267865A1 (en) 2008-10-30
CA2547435A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
CA2413190A1 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
WO2020041541A3 (en) Anti-tigit antibodies
EP1553975B8 (en) Optimized fc variants and methods for their generation
BRPI0410031A (pt) variantes fc otimizadas e métodos para sua geração
ATE412432T1 (de) Internalisierende erbb2 antikörper
WO2007044616A3 (en) Optimized anti-cd30 antibodies
WO2003068201A3 (en) High affinity antibody having a tcr-like specificity and use in detection and treatment
NO20091748L (no) Mikroorganismer eller fraksjoner derav, istand til aktivering avcellulaer immunitet mot karbohydrater
CY1110877T1 (el) Αλλαγη των συγγενειων συνδεσης me fcrn ή των ημιζωων ορου αντισωματων με μεταλλαξιγενεση
MA30689B1 (fr) Derives de leptomycine
ATE354644T1 (de) Katalytischer antikörper gegen aldolase
WO2000073796A3 (de) Ligand-anker-konjugate zur generierung einer biosensor-schicht
WO2003073817A3 (en) Rapid and sensitive detection of cells and viruses
CY1110689T1 (el) Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια
WO2007062177A3 (en) Molecular conjugate
CY1113400T1 (el) Αλλαγη των συγγενειων συνδεσης me fcrn ή των ημιζωων ορου αντισωματων με μεταλλαξιγενεση
ATE477275T1 (de) Antikörper gegen cd28
AU2003218707A1 (en) Segment of a sensor-supporting element for a scraper-type device
CY1108799T1 (el) Αντισωμα αντι- ccr5
WO2004013307A3 (en) Compounds for targeting hepatocytes
WO2005046597A3 (en) Antibodies to cd44 glycoforms and uses thereof
AU3143897A (en) Oligonucleotides which specifically bind retroviral nucleocapsid proteins
WO2004029072A3 (en) PrPsc -INTERACTING MOLECULES AND USES THEREOF
ATE304709T1 (de) Substanzen mit verzweigten linkermolekülen
EP1957038B8 (en) Particles

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application